Sandoz Says An Eli Lilly ADHD Drug Patent Is Invalid

Law360, New York (August 29, 2007, 12:00 AM EDT) -- Sandoz Inc. has launched a preemptive strike against Eli Lilly & Co., asking a New Jersey court to declare that an Eli Lilly patent relating to attention-deficit drug Strattera is invalid and not infringed by a Sandoz-proposed drug.

Sandoz, the U.S.-based generics arm of Novartis AG, filed the declaratory judgment suit against Eli Lilly on Monday, in the U.S. District Court for the District of New Jersey.

At issue is U.S. Patent Number 5,658,590, entitled “Treatment of attention-deficit/hyperactivity disorder,” issued in 1997 and assigned to Eli...
To view the full article, register now.